Hyperpolarized Carbon C 13 Pyruvate in Diagnosing Glioma in Patients With Brain Tumors
Phase 1
Recruiting
- Conditions
- Primary Brain Neoplasm
- Interventions
- Drug: Hyperpolarized Carbon C 13 PyruvateProcedure: Magnetic Resonance Spectroscopic Imaging
- First Posted Date
- 2019-02-05
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 13
- Registration Number
- NCT03830151
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Pentoxifylline, Atorvastatin, and Vitamin E in Treating Patients With Erectile Dysfunction After Radiation Therapy for Prostate Cancer
Phase 2
Completed
- Conditions
- Erectile Dysfunction, CTCAEMale Erectile DisorderProstate AdenocarcinomaImpotence
- Interventions
- First Posted Date
- 2019-02-05
- Last Posted Date
- 2023-10-17
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 14
- Registration Number
- NCT03830164
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Abiraterone Acetate, Prednisone, and Apalutamide in Treating Patients With Hormone-Naive Metastatic Prostate Cancer
Phase 2
Active, not recruiting
- Conditions
- Prostate AdenocarcinomaMetastatic Prostate CarcinomaProstate Carcinoma Metastatic in the BoneStage IVB Prostate Cancer AJCC v8Stage IVA Prostate Cancer AJCC v8Stage IV Prostate Cancer AJCC v8
- Interventions
- First Posted Date
- 2019-01-30
- Last Posted Date
- 2024-09-27
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 60
- Registration Number
- NCT03821792
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Shorter Course, Hypofractionated Pre-Surgery Radiation Therapy in Treating Patients With Localized, Resectable Soft Tissue Sarcoma of the Extremity of Superficial Trunk
Phase 2
Active, not recruiting
- Conditions
- Resectable Soft Tissue SarcomaStage I Soft Tissue Sarcoma of the Trunk and Extremities AJCC V8Stage IA Soft Tissue Sarcoma of the Trunk and Extremities AJCC V8Stage IB Soft Tissue Sarcoma of the Trunk and Extremities AJCC V8Stage II Soft Tissue Sarcoma of the Trunk and Extremities AJCC V8Stage III Soft Tissue Sarcoma of the Trunk and Extremities AJCC V8Stage IIIA Soft Tissue Sarcoma of the Trunk and Extremities AJCC V8Stage IIIB Soft Tissue Sarcoma of the Trunk and Extremities AJCC V8
- Interventions
- Radiation: Hypofractionated Radiation TherapyOther: Quality-of-Life AssessmentOther: Questionnaire Administration
- First Posted Date
- 2019-01-29
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 122
- Registration Number
- NCT03819985
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Role of Gut Microbiome and Fecal Transplant on Medication-Induced GI Complications in Patients With Cancer
Phase 1
Recruiting
- Conditions
- Clinical Stage 0 Cutaneous Melanoma AJCC v8Clinical Stage IIB Cutaneous Melanoma AJCC v8Clinical Stage IIC Cutaneous Melanoma AJCC v8Lung Non-Small Cell CarcinomaMalignant Genitourinary System NeoplasmMalignant Solid NeoplasmPathologic Stage 0 Cutaneous Melanoma AJCC v8Pathologic Stage I Cutaneous Melanoma AJCC v8Pathologic Stage IB Cutaneous Melanoma AJCC v8Pathologic Stage IIA Cutaneous Melanoma AJCC v8
- Interventions
- Other: Best PracticeOther: Biospecimen CollectionProcedure: Endoscopic ProcedureProcedure: Fecal Microbiota TransplantationBiological: InfliximabOther: Laboratory Biomarker AnalysisDrug: PrednisoneBiological: Vedolizumab
- First Posted Date
- 2019-01-28
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 800
- Registration Number
- NCT03819296
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Effectiveness of an Online Intervention Targeting Cancer-related Fatigue
Not Applicable
Terminated
- Conditions
- Malignant NeoplasmCancer Survivor
- Interventions
- Other: Internet-Based InterventionOther: Quality-of-Life AssessmentOther: Questionnaire Administration
- First Posted Date
- 2019-01-18
- Last Posted Date
- 2020-07-29
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 27
- Registration Number
- NCT03809130
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Low-Intensity Chemotherapy and Venetoclax in Treating Patients with Relapsed or Refractory B- or T-Cell Acute Lymphoblastic Leukemia
Phase 1
Active, not recruiting
- Conditions
- Recurrent B Acute Lymphoblastic LeukemiaRecurrent T Acute Lymphoblastic LeukemiaRefractory B Acute Lymphoblastic LeukemiaRefractory T Acute Lymphoblastic Leukemia
- Interventions
- First Posted Date
- 2019-01-17
- Last Posted Date
- 2025-01-09
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 50
- Registration Number
- NCT03808610
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Ipilimumab, Nivolumab, and Radiation Therapy in Treating Patients with HPV Positive Advanced Oropharyngeal Squamous Cell Carcinoma
Phase 2
Active, not recruiting
- Conditions
- Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC V8Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC V8Human Papillomavirus Positive Oropharyngeal Squamous Cell CarcinomaOropharyngeal Basaloid CarcinomaPathologic Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC V8Pathologic Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC V8Posterior Tongue Squamous Cell CarcinomaSoft Palate Squamous Cell CarcinomaStage III Oropharyngeal Squamous Cell Carcinoma AJCC V7Stage IVA Oropharyngeal Squamous Cell Carcinoma AJCC V7
- Interventions
- Radiation: Intensity-Modulated Radiation TherapyBiological: IpilimumabBiological: NivolumabOther: Quality-of-Life AssessmentOther: Questionnaire Administration
- First Posted Date
- 2019-01-10
- Last Posted Date
- 2024-10-22
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 37
- Registration Number
- NCT03799445
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
A Phase I Study of SOR-C13 in Patients With Advanced Solid Tumors
Phase 1
Completed
- Conditions
- Advanced Malignant Solid NeoplasmRefractory Malignant Solid NeoplasmRefractory Ovarian CarcinomaStage II Pancreatic Cancer AJCC v8Stage III Ovarian Cancer AJCC v8Stage IIIA Ovarian Cancer AJCC v8Stage IIIA Prostate Cancer AJCC v8Stage IIIB Ovarian Cancer AJCC v8Stage IIIB Prostate Cancer AJCC v8Stage IIIC Ovarian Cancer AJCC v8
- Interventions
- Drug: TRPV6 Calcium Channel Inhibitor SOR-C13
- First Posted Date
- 2018-12-24
- Last Posted Date
- 2023-11-18
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 11
- Registration Number
- NCT03784677
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Phase I/II Study of Perioperative Chemotherapy Plus Immunotherapy Followed by Surgery in Localized Esophageal and Gastroesophageal Adenocarcinoma
Phase 2
Recruiting
- Conditions
- Pathologic Stage IB Gastroesophageal Junction Adenocarcinoma AJCC v8Pathologic Stage IC Esophageal Adenocarcinoma AJCC v8Pathologic Stage IC Gastroesophageal Junction Adenocarcinoma AJCC v8Pathologic Stage II Esophageal Adenocarcinoma AJCC v8Pathologic Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8Pathologic Stage IIA Esophageal Adenocarcinoma AJCC v8Pathologic Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8Pathologic Stage IIB Esophageal Adenocarcinoma AJCC v8Pathologic Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8Pathologic Stage III Esophageal Adenocarcinoma AJCC v8
- Interventions
- Drug: AtezolizumabProcedure: Conventional SurgeryDrug: FluorouracilDrug: OxaliplatinDrug: Tiragolumab
- First Posted Date
- 2018-12-21
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 40
- Registration Number
- NCT03784326
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
© Copyright 2025. All Rights Reserved by MedPath